Pantent Lawsuit Loss Over Nasonex Could Hurt Merck’s Anti-Infectives Business

June 18, 2012

By Trefis Team

Merck (NYSE:MRK) received a major setback as a U.S. District court rejected its patent infringement lawsuit against Apotex Inc. over the latter’s plan to launch a generic version of Nasonex, one of Merck’s major drugs. However, the court rejected Apcotex’s claim of Merck’s patent being invalid. The litigation was initiated by Merck back in 2009 when Apotex filed an application with the FDA to approve the marketing of a generic version of Merck’s Nasonex prior to its patent expiration in 2018. [1] Below we take a look at how this could impact the healthcare giant even as it contemplates to appeal against the ruling.

This article may be found in its entirety on the Trefix website.